| Status | In progress |
| Process | STA 2018 |
| ID number | 1376 |
Project Team
| Project lead | Jeremy Powell |
Email enquiries
- If you have any queries please email TACommB@nice.org.uk
| Evidence Review Group / Assessment Group | Warwick Evidence, Warwick Medical School, University of Warwick |
Consultees
| Companies sponsors | Sanofi (sotagliflozin) |
| Others | Department of Health and Social Care |
| NHS England | |
| Welsh Government | |
| Patient carer groups | JDRF |
| Professional groups | Association of British Clinical Diabetologists |
| Royal College of Pathologists | |
| Royal College of Physicians | |
| UK Clinical Pharmacy Association |
Commentators
| Associated public health groups | Public Health England |
| Public Health Wales | |
| Comparator companies | Eli Lilly (insulin) |
| Novo Nordisk (insulin) (not participating) | |
| Sanofi (insulin) | |
| Wockhardt UK (insulin) (not participating) | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Scottish Medicines Consortium | |
| Welsh Health Specialised Services Committee |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 26 September 2019 | Committee meeting: 2 |
| 06 August 2019 | After the first Appraisal Committee meeting the Committee requested additional analyses from the company. |
| 30 July 2019 | Committee meeting: 1 |
| 06 December 2018 | Invitation to participate |
| 25 September 2018 | Please note that following on from information provided by the company the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late November 2018. |
| 13 February 2018 | In progress, Topic referred |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance